ArticleDrug development research2011
In Silico Augmentation of the Drug Development Pipeline: Examples from the study of Acute Inflammation.
Article in Drug development research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- The Six Ds of Exponentials and drug discovery: A path toward reversing Eroom's law.Drug discovery today · 2025Review
- Digital twin mathematical models suggest individualized hemorrhagic shock resuscitation strategies.Communications medicine · 2024Article
- The Wound Environment Agent-based Model (WEABM): a digital twin platform for characterization and complex therapeutic discovery for volumetric muscle loss.bioRxiv : the preprint server for biology · 2024Article
- Towards systems immunology of critical illness at scale: from single cell 'omics to digital twins.Trends in immunology · 2023Review
- What's next for computational systems biology?Frontiers in systems biology · 2023Review
- In-Silico Approaches for the Screening and Discovery of Broad-Spectrum Marine Natural Product Antiviral Agents Against Coronaviruses.Infection and drug resistance · 2023Review
- The COVID-19 vaccine development: A pandemic paradigm.Virus research · 2021Review
- Utilizing the Heterogeneity of Clinical Data for Model Refinement and Rule Discovery Through the Application of Genetic Algorithms to Calibrate a High-Dimensional Agent-Based Model of Systemic Inflammation.Frontiers in physiology · 2021Article
- Dynamics of Systemic Inflammation as a Function of Developmental Stage in Pediatric Acute Liver Failure.Frontiers in immunology · 2020Observational
- A compound attributes-based predictive model for drug induced liver injury in humans.PloS one · 2020Article
- Inflammation and Disease: Modelling and Modulation of the Inflammatory Response to Alleviate Critical Illness.Current opinion in systems biology · 2018Article
- Examining the controllability of sepsis using genetic algorithms on an agent-based model of systemic inflammation.PLoS computational biology · 2018Article
- Multiscale Modeling in the Clinic: Drug Design and Development.Annals of biomedical engineering · 2016Review
- Insights into the Role of Chemokines, Damage-Associated Molecular Patterns, and Lymphocyte-Derived Mediators from Computational Models of Trauma-Induced Inflammation.Antioxidants & redox signaling · 2015Review
- The inverse problem in mathematical biology.Mathematical biosciences · 2015Review
- Mathematical Modeling of Early Cellular Innate and Adaptive Immune Responses to Ischemia/Reperfusion Injury and Solid Organ Allotransplantation.Frontiers in immunology · 2015Article
- From data patterns to mechanistic models in acute critical illness.Journal of critical care · 2014Review
- Investigation of inflammation and tissue patterning in the gut using a Spatially Explicit General-purpose Model of Enteric Tissue (SEGMEnT).PLoS computational biology · 2014Article
- How implementation of systems biology into clinical trials accelerates understanding of diseases.Frontiers in neurology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The clinical translation of promising basic biomedical findings, whether derived from reductionist studies in academic laboratories or as the product of extensive high-throughput and -content screens in the biotechnology and pharmaceutical industries, has reached a period of stagnation in which ever higher research and development costs are yielding ever fewer new drugs. Systems biology and computational modeling have been touted as potential avenues by which to break through this logjam. However, few mechanistic computational approaches are utilized in a manner that is fully cognizant of the inherent clinical realities in which the drugs developed through this ostensibly rational process will be ultimately used. In this article, we present a Translational Systems Biology approach to inflammation. This approach is based on the use of mechanistic computational modeling centered on inherent clinical applicability, namely that a unified suite of models can be applied to generate in silico clinical trials, individualized computational models as tools for personalized medicine, and rational drug and device design based on disease mechanism.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.